Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS
In this medfyle
The CENTAURUS study provides insights into the efficacy and safety of daratumumab for patients with intermediate/high-risk SMM. After a median follow-up of around 7 years, the data show notable PFS, tolerability, and long-term safety across different dosing regimens. These findings emphasize daratumumab's potential as a proactive treatment to delay progression from SMM to MM, paving the way for future advancements.
About this Medfyle
©2025 Medfyle. All rights reserved.
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in Blood, American Society of Hematology's official journal.
Original article: Landgren O, Chari A, Cohen YC, Spencer A, Voorhees PM, Sandhu I, Jenner MW, Smith D, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Vieyra D, Sha L, Li L, Rousseau E, Dennis R, Carson R, Hofmeister CC. Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS. Blood. 2025 Apr 10;145(15):1658-1669.
